VIVES Partners, managing company of VIVES Funds, has joined a €84 million ($98.8 million) Series B financing round for Swiss radiopharmaceuticals innovator Nuclidium AG.

The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Eurazeo, NRW.BANK, HighLight Capital, alongside existing investors and VIVES Partners.

The funding will advance clinical development of Nuclidium’s proprietary Copper-61/Copper-67 (61Cu/67Cu) theranostic platform — a dual diagnostic and therapeutic approach that uses copper isotopes conjugated to tumour-targeting molecules.

This platform aims to overcome current limitations in radiotheranostics, including suboptimal clinical efficacy, challenging production logistics, and restricted accessibility.

Radiotheranostics represent a growing frontier in precision oncology, enabling targeted delivery of radiation to cancer cells while sparing healthy tissue. Copper isotopes, with their favorable decay properties and biochemical behavior, are increasingly recognized as ideal candidates for this modality.

The company intends to expand its global manufacturing and production network to support scalable supply and meet the anticipated clinical demand across multiple oncology indications. Lead compounds are progressing toward next-stage clinical trials for metastatic prostate cancer, neuroendocrine tumors, and breast cancer.

This investment marks VIVES Partners’ first foray into the radiopharmaceutical sector and aligns with its strategy to broaden geographic scope and invest in later-stage biotech companies advancing toward clinical milestones.

Sandra Schoors, Partner at VIVES Partners, commented: “We see strong potential in Nuclidium’s copper-based radiotheranostic platform to address critical gaps in cancer diagnosis and therapy. Their innovative chemistry and scalable approach to production position them well to make a significant impact on patient outcomes.”

By combining novel radiochemistry with tumour-specific targeting, the company’s platform is designed to improve precision, safety, and efficacy of radiopharmaceutical therapies, potentially offering more convenient dosing and enhanced therapeutic windows compared to existing options.